Human induced-T-to-natural killer cells have potent anti-tumour activities

• Main Authors: Zhiwu Jiang (Author), Le Qin (Author), Yuou Tang (Author), Rui Liao (Author), Jingxuan Shi (Author), Bingjia He (Author), Shanglin Li (Author), Diwei Zheng (Author), Yuanbin Cui (Author), Qiting Wu (Author), Youguo Long (Author), Yao Yao (Author), Zhihui Wei (Author), Qilan Hong (Author), Yi Wu (Author), Yuanbang Mai (Author), Shixue Gou (Author), Xiaoping Li (Author), Robert Weinkove (Author), Sam Norton (Author), Wei Luo (Author), Weineng Feng (Author), Hongsheng Zhou (Author), Qifa Liu (Author), Jiekai Chen (Author), Liangxue Lai (Author), Xinwen Chen (Author), Duanqing Pei (Author), Thomas Graf (Author), Xingguo Liu (Author), Yangqiu Li (Author), Pentao Liu (Author), Zhenfeng Zhang (Author), Peng Li (Author)
• Format: Book
• Published: BMC, 2022-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Adoptive cell therapy (ACT) is a particularly promising area of cancer immunotherapy, engineered T and NK cells that express chimeric antigen receptors (CAR) are being explored for treating hematopoietic malignancies but exhibit limited clinical benefits for solid tumour patients...